ZYDUS WELLNESS LTD.-$ - 531335 - Clarification sought from Zydus Wellness Ltd
The Exchange has sought clarification from Zydus Wellness Ltd on February 26, 2024, with reference to Movement in Volume. The reply is awaited.26-02-2024
26-02-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure under SEBI Insider Trading Regulations24-02-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 201522-02-2024
Zydus Lifesciences received approval for Isosorbide Mononitrate, shares up
Zydus Lifesciences' shares rose 1.40% as USFDA approves Isosorbide Mononitrate Tablets, used to treat chest pain, for distribution16-02-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Earnings conference call held on February 8, 202413-02-2024
Zydus LifeSciences Q3 Results Review - India, US, Emerging Market Drives Earnings: Motilal Oswal
Work in progress for innovative pipeline.12-02-2024
Zydus Lifesciences Q3 FY24 Results Live: Profit Rises by 26.76% YoY
Zydus Lifesciences Q3 FY24 Results Live: Revenue increased by 3.28% YoY & profit increased by 26.76% YoY11-02-2024
Zydus Life Q3 net profit surges 26% to Rs 789.6 crore
Zydus Life Q3 results: The pharma company reported a net profit of Rs 622.9 crore in the year-ago period.09-02-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication for unaudited financial results for the quarter and nine months ended on December 31, 202309-02-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording08-02-2024